The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY
Abstract
BACKGROUND AND AIM: Glucagon-like peptide-2 (GLP-2) and peptide YY (PYY) are produced in endocrine L-cells of the intestine and secreted in response to food intake. GLP-2 has a trophic effect on the intestinal epithelium, whereas PYY has pro-absorptive effects. It can be speculated that, in inflammatory bowel disease (IBD), the production and secretion of GLP-2 and PYY could be affected as a part of a regulatory mechanism. Therefore, tissue levels and meal-stimulated secretion of GLP-2 and PYY were studied in IBD patients and compared to controls. METHODS: Outpatients with IBD and control patients were included. Mucosal biopsies were taken from the ileum and colon and the content of GLP-2 and PYY was measured. After colonoscopy the patients took a mixed meal and plasma was collected for 90 min for plasma measurements of GLP-2 and PYY. RESULTS: Tissue levels of GLP-2 in control patients were highest in the terminal ileum (407+/-82 pmol/g tissue, n=10), whereas PYY was highest in the rectum (919+/-249 pmol/g tissue, n=10). In IBD patients with acute inflammation, the content of GLP-2 was similar to controls, whereas PYY was decreased to 72.1+/-17.7% (P=0.03, n=13) of control values. Neither the fasting plasma levels nor the meal responses of GLP-2 and PYY differed between controls and IBD patients. CONCLUSION: The similar responses of GLP-2 and PYY in patients and controls do not support the suggestion that L-cell secretion is altered in IBD. The decreased tissue PYY concentrations may contribute to the diarrhoea of some of these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, Schmidt et al. found no difference in meal-stimulated GLP-2 plasma or tissue concentrations between IBD and non-IBD individuals. 115”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [115]
Citations
Cites
Induction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Jeppesen, P. B., Hartmann, B., Thulesen, J., Graff, J., Lohmann, J., Hansen, B. S., Tofteng, F., Poulsen, S. S., Madsen, J. L., Holst, J. J., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.22555 · Cited by 532
Self-citationBiological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500
GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine
Mortensen, K., Christensen, L. L., Holst, J. J., & Orskov, C. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00125-3 · Cited by 359
Self-citationColonic endocrine cells in inflammatory bowel disease
El‐Salhy, M., Danielsson, Å., Stenling, R., & Grimelius, L. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.00237.x · Cited by 235
Structure, measurement, and secretion of human glucagon-like peptide-2
Hartmann, B., Johnsen, A. H., Ørskov, C., Adelhorst, K., Thim, L., & Holst, J. J. (2000) · Peptides · doi:10.1016/s0196-9781(99)00176-x · Cited by 221
Self-citationPeptide YY abnormalities in gastrointestinal diseases
Adrian, T. E., Savage, A. P., Bacarese-Hamilton, A. J., Wolfe, K., Besterman, H. S., & Bloom, S. R. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90936-4 · Cited by 176
Holst, J. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00157-5 · Cited by 146
Self-citationPeptide YY-like immunoreactivity in the central nervous system of the rat
Ekman, R., Wahlestedt, C., Böttcher, G., Sundler, F., Håkanson, R., & Panula, P. (1986) · Regulatory Peptides · doi:10.1016/0167-0115(86)90059-5 · Cited by 133
Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
Xiao, Q., Boushey, R. P., Cino, M., Drucker, D. J., & Brubaker, P. L. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.4.r1057 · Cited by 111
Research works printed but not linked: 8
- Holst, 2001, Scand J Clin Lab Invest, 234, 75???85
- Jeppesen, 2002, Gut, 47, 370???376
- Adrian, 1985, Gastroenterology, 89, 1070???1077
- Schmidt, 2000, Scand J Gastroenterol, 35, 522???527
- Drucker, 1999, Am J Physiol, 276, G79???G91
- Boushey, 1999, Am J Physiol, 277, E937???E947
- Alavi, 2000, J Pediatr Surg, 35, 847???851
- Koch, 1988, Dig Dis Sci, 33, 1322???1328
Cited by
Neuropeptide, Y, peptide YY and pancreatic polypeptide in the gut-brain axis
Holzer, P., Reichmann, F., & Farzi, A. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.08.005 · Cited by 501
Neuropeptides and the Microbiota-Gut-Brain Axis
Holzer, P., & Farzi, A. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-0897-4_9 · Cited by 451
“These experimental data are in line with a decrease of colonic PYY levels in patients with inflammatory bowel disease [100-102], while circulating levels of PYY and NPY are enhanced [103,104].”
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“115 These results suggest that GLP-1RA might be beneficial as a therapeutic agent for treating IBD, providing a new strategy to target inflammation and improve clinical outcomes in affected patients.”
BackgroundWorthington, J. J., Reimann, F., & Gribble, F. M. (2018) · Mucosal Immunology · doi:10.1038/mi.2017.73 · Cited by 262
“Hepato-gastroenterology 2014; 61(133): 1196-1200.”
The Effects of Exercise-Induced Weight Loss on Appetite-Related Peptides and Motivation to Eat
Martins, C., Kulseng, B., King, N. A., Holst, J. J., & Blundell, J. E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2082 · Cited by 236
Self-citation
Metadata
- Authors
- Schmidt, P. T., Ljung, T., Hartmann, B., Hare, K. J., Holst, J. J., & Hellstr??m, P. M.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Schmidt, Peter T.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2005-02
- Volume
- 17
- Issue
- 2
- Pages
- 207-212
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2003961228
- Cited by
- 52
- References
- 12
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2020: 3 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 1 · 2014: 5 · 2013: 2 · 2012: 5
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- glucagon-like peptide-2, peptide YY, inflammatory bowel disease, intestinal L cells, intestinal mucosa, ileum, colon, acute intestinal inflammation, diarrhea
- MeSH terms
- Colitis, Ulcerative, Colon, Crohn Disease, Glucagon-Like Peptides, Humans, Ileum, Intestinal Mucosa, Peptides, Radioimmunoassay, Inflammatory Bowel Diseases, Postprandial Period, Peptide YY, Glucagon-Like Peptide 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. https://app.cochat.ai/papers/10.1097/00042737-200502000-00012
- The paper
- Schmidt, P. T., Ljung, T., Hartmann, B., Hare, K. J., Holst, J. J., & Hellstr??m, P. M. (2005). Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/00042737-200502000-00012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.